The Importance of TIMI 3 flow in primary angioplasty

Original title: Predicitors of suboptimal TIMI flow alter primary angioplasty for acute myocardial infarction: results from the HORIZON-AMI trial. Reference: Adriano Caixeta et al.  Eurointervention 2013;9:220-227

Primary angioplasty showed greater efficacy than thrombolytics but one out of every four patients cannot achieve TIMI 3 flow.

The Horizons-AMI trial randomized 3,602 patients to receive bivalirudin or heparin plus inhibitors IIb IIIa and after angiography a second randomization took place to DES or a conventional stent. The primary objective of this analysis was to evaluate the angiographic predictors of both clinical and suboptimal procedural flow (TIMI <3) after stent implantation. The secondary objective was the impact after three years of suboptimal flow, (TIMI 0-2 versus TIMI 3). Angioplasty was performed in 3,345 patients, (92.9%), of which 2,758, (87.1%), had final TIMI 3 flow.

Those who had TIMI

After 30 days and three years, end TIMI flow

Conclusion:

In this large study the lack of restoration of TIMI 3 flow was associated with older age, past infarction, TIMI flow 0-1, lesion length and was a strong predictor of mortality.

Commentary:

This study shows that the failure to achieve TIMI 3 is associated with higher mortality at three years, than the PAMI, Cadillac and Apex IMA studies had shown at six months. It may be important to have a good pre-hospital service where trained personnel are available to bypass the emergency department and refer the patient directly to the catheterization laboratory. 

Courtesy of Dr Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation.
Buenos Aires, Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...